# Lenalidomide Following Fludarabine/Rituximab (FR) in Untreated Chronic Lymphocytic Leukemia (CLL)

> **NCT00860457** · PHASE2 · COMPLETED · sponsor: **Georgetown University** · enrollment: 22 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** Rituximab
- **DRUG:** Fludarabine
- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT00860457
- **Lead sponsor:** Georgetown University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02
- **Primary completion:** 2011-03
- **Final completion:** 2012-02
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2018-11-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00860457

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00860457, "Lenalidomide Following Fludarabine/Rituximab (FR) in Untreated Chronic Lymphocytic Leukemia (CLL)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00860457. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*